Is 2q23.1 Microdeletion Syndrome hereditary?

2q23.1 Microdeletion Syndrome is a genetic condition caused by the loss of a small segment of genetic material on chromosome 2, specifically involving the MBD5 gene. In the vast majority of cases, 2q23.1 Microdeletion Syndrome occurs de novo, meaning it is not inherited from parents but happens spontaneously during the formation of reproductive cells or early embryonic development.

Is 2q23.1 Microdeletion Syndrome hereditary?

While 2q23.1 Microdeletion Syndrome is a genetic condition, it is rarely hereditary. Because the deletion typically occurs as a de novo event, the parents of an affected child usually have normal chromosomal structures. The distinction is that while the disorder is rooted in the individual's DNA, it is not passed down through familial lines in most diagnosed cases.

What is the risk of recurrence for future pregnancies?

For parents of a child with 2q23.1 Microdeletion Syndrome caused by a de novo mutation, the risk of having another child with the same condition is generally considered very low, typically less than 1%. However, clinical geneticists recommend parental chromosomal analysis to rule out a rare, balanced translocation or mosaicism in one of the parents, which could slightly increase recurrence risk.

How is 2q23.1 Microdeletion Syndrome diagnosed and managed?

Diagnosis is confirmed through specialized genetic testing. Because 2q23.1 Microdeletion Syndrome involves a microdeletion too small to be seen on a standard karyotype, the following methods are used:

• Chromosomal Microarray Analysis (CMA): The gold standard for detecting submicroscopic deletions.


• Fluorescence In Situ Hybridization (FISH): Used to confirm the presence of the 2q23.1 deletion.


• Whole Exome/Genome Sequencing: Occasionally used if microarray results are inconclusive but clinical suspicion remains high.

What is the role of genetic counseling?

Genetic counseling is essential for families navigating 2q23.1 Microdeletion Syndrome. A counselor helps families understand the nature of the deletion, provides emotional support, and discusses reproductive options. For those planning future pregnancies, options such as prenatal diagnosis via amniocentesis or chorionic villus sampling (CVS), and preimplantation genetic testing (PGT) through IVF, can be explored to provide clarity.

Next steps

• Consult with a clinical geneticist to review microarray results and discuss specific familial risks.


• Connect with the 2q23.1 Microdeletion Syndrome community on DiseaseMaps.org to share experiences with other families.


• Request a referral to a pediatric neurologist or developmental pediatrician for ongoing management of symptoms.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider.

References

• NIH Genetic and Rare Diseases Information Center (GARD): 2q23.1 microdeletion syndrome.


• Orphanet: MBD5-associated neurodevelopmental disorder (MAND).


• Online Mendelian Inheritance in Man (OMIM): MBD5-associated neurodevelopmental disorder (Entry #611369).